Sanford C. Bernstein reiterated their market perform rating on shares of Sanofi (NYSE:SNY) in a research report released on Thursday, February 8th. Sanford C. Bernstein currently has a $45.00 target price on the stock, down from their previous target price of $50.00.
SNY has been the subject of a number of other research reports. Barclays raised Sanofi from an underweight rating to an equal weight rating in a research report on Wednesday, November 15th. Morgan Stanley cut Sanofi from an overweight rating to an underweight rating in a research report on Friday, December 1st. Bank of America cut Sanofi from a buy rating to a neutral rating in a research report on Wednesday, December 6th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of Sanofi in a research report on Thursday, December 14th. Finally, Cowen set a $48.00 price target on Sanofi and gave the stock a hold rating in a research report on Monday, December 18th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the stock. Sanofi presently has an average rating of Hold and an average target price of $49.33.
Shares of Sanofi (SNY) opened at $39.86 on Thursday. The stock has a market capitalization of $99,347.42, a price-to-earnings ratio of 10.92, a P/E/G ratio of 2.06 and a beta of 0.85. Sanofi has a 12-month low of $38.14 and a 12-month high of $50.65. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26.
The firm also recently disclosed an annual dividend, which will be paid on Monday, June 4th. Investors of record on Thursday, May 10th will be given a dividend of $1.8609 per share. This represents a dividend yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.58. Sanofi’s payout ratio is currently 30.14%.
Several hedge funds and other institutional investors have recently bought and sold shares of SNY. Bank of Nova Scotia Trust Co. acquired a new position in shares of Sanofi during the 3rd quarter worth about $125,000. Bronfman E.L. Rothschild L.P. lifted its position in shares of Sanofi by 46.0% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 4,325 shares of the company’s stock worth $186,000 after purchasing an additional 1,362 shares during the last quarter. Toronto Dominion Bank lifted its position in shares of Sanofi by 4.6% during the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after purchasing an additional 180 shares during the last quarter. SeaCrest Wealth Management LLC acquired a new position in shares of Sanofi during the 4th quarter worth about $200,000. Finally, Mraz Amerine & Associates Inc. acquired a new position in shares of Sanofi during the 3rd quarter worth about $204,000. 9.07% of the stock is owned by institutional investors and hedge funds.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.